A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Vilazodone (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Forest Laboratories
- 19 Aug 2015 Results published in the International Clinical Psychopharmacology.
- 01 May 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.